Santhera and ReveraGen to Present Phase 2a/2b Efficacy and New Safety Data with Vamorolone at Forthcoming Conferences

NEXT STORY
Inventiva completes sale of $30 million through its ATM program to existing and new specialized institutional investors
PREV STORY
Number of Shares and Voting Rights of Innate Pharma as of September 1, 2021
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Global Bio safety Testing Market is Estimated to be US$ 10.5 Billion by 2029 with a CAGR of 13.1% during the forecast Period – PMI

author_avatar
NASDAQ Market News

Chinook Therapeutics Announces Upcoming Data Presentations at ISN World Congress of Nephrology 2021 and 58th ERA-EDTA Congress

author_avatar
NASDAQ Market News

Kirkland Lake Gold Announces Filing of Detour Lake Mine Technical Report

author_avatar
NASDAQ Market News